Matches in Nanopublications for { ?s ?p "DDI between Bevacizumab and Sunitinib - Sunitinib may enhance the adverse/toxic effect of bevacizumab. Specifically, the risk for a specific form of anemia, microangiopathic hemolytic anemia (MAHA), may be increased. Bevacizumab may enhance the hypertensive effect of sunitinib. This combination is contraindicated."@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00112_DB01268 title "DDI between Bevacizumab and Sunitinib - Sunitinib may enhance the adverse/toxic effect of bevacizumab. Specifically, the risk for a specific form of anemia, microangiopathic hemolytic anemia (MAHA), may be increased. Bevacizumab may enhance the hypertensive effect of sunitinib. This combination is contraindicated." assertion.